Fibralign Announces Start of European Lymphedema Prevention Clinical Study
/
DateFeb 09 2021
Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first patient in a multi-site, randomized clinical trial in Europe evaluating its BioBridge® Collagen Matrix as a novel preventative treatment for secondary lymphedema. Read More →


















